Alpha Cognition Inc. (ACOG) fundamentals score
Execute commercialization of the FDA-approved ZUNVEYL oral formulation. ZUNVEYL is the second oral therapy available for Alzheimer’s patients in the past decade. The Company may pursue new business opportunities for commercial and/or development partners both domestically and internationally.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 3.5 out of 10, Weak long-term fundamentals
- Growth: 3.5/10
- Profitability: 1.0/10
- Financial health: 9.0/10
- Earnings quality: 2.0/10
- Valuation: 1.5/10
Scores are calculated from Alpha Cognition Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10